Gibble TH, Kosa K, Basnyat B, Martin S, Moses R, Dubinsky M. Patient perspectives on symptoms and impacts in Crohn's disease: results from qualitative research. Poster presented at the European Crohn's and Colitis Organisation (ECCO) 2024; February 21, 2024. Stockholm, Sweden. [abstract] J Crohns Colitis. 2024 Jan; 18(Suppl 1):i265.
Gibble TH, Kosa K, Basnyat B, Martin S, Moses R, Dubinsky M. Cognitive debriefing of a patient-reported outcome measure for abdominal pain and loose stool frequency in Crohn's disease. Poster presented at the European Crohn's and Colitis Organisation (ECCO) 2024; February 21, 2024. Stockholm, Sweden. [abstract] J Crohns Colitis. 2024 Jan; 18(Suppl 1):i572.
Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting; September 18, 2022. Bologna, Italy. [abstract] J Neurol Neurosurg Psychiatry. 2022 Sep 12; 93(suppl 1):A45-6. doi: 10.1136/jnnp-2022-ehdn.118
Nagar S, Patel J, Stanford RH. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: a U.S. database study. Manag Care. 2018 May;27(5):40-7.
Vickers AD, Mody RR, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 10th Congress of the European Crohn's and Colitis Organization; February 18, 2015. Barcelona, Spain. [abstract] J Crohns Colitis. 2015 Feb 2; 9(Suppl 1):S357-8. doi: 10.1093/ecco-jcc/jju027.672
Meyers J, Candrilli S, Allen R, Manjunath R, Calloway M. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists. Manag Care. 2012 Oct 1;21(10):44-51.
Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 ?g/50 ?g combination versus tiotropium in commercially insured patients with copd. Manag Care. 2011 Aug 1;20(8):46-55.
Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010 Mar 1;19(3):44-51.